Covid-19 vaccine: Bangladesh to get priority if China develops vaccine

Covid-19 in Bangladesh

UNB
21 June, 2020, 08:50 pm
Last modified: 21 June, 2020, 11:16 pm
"Of course, Bangladesh is our important friend and Bangladesh will surely get priority," Deputy Chief of Mission at Chinese Embassy in Dhaka Hualong Yan told UNB on Sunday

China has said Bangladesh will get priority in terms of cooperation and support if they can successfully develop vaccine for the coronavirus. 

"Of course, Bangladesh is our important friend and Bangladesh will surely get priority," Deputy Chief of Mission at Chinese Embassy in Dhaka Hualong Yan told UNB on Sunday. 

He said Bangladesh and China are working closely to deal with the situation amid the coronavirus outbreak. 

He said five Chinese companies are working to develop vaccine for coronavirus. 

An inactivated COVID-19 vaccine candidate developed by the Institute of Medical Biology under the Chinese Academy of Medical Sciences has entered phase-2 clinical trials in China, the Science and Technology Daily reported Saturday.

The phase-2 trials, which further evaluate the immunogenicity and safety of the vaccine in humans, are conducted in the southwestern province of Yunnan.

So far, five COVID-19 vaccine candidates have been approved for clinical trials in China, accounting for 40 percent of the total vaccines in clinical trials worldwide, according to the Ministry of Science and Technology, reports Xinhua.

As Bangladesh's fight against the COVID-19 pandemic continued to become fiercer, Xi Jinping, President of the People's Republic of China, had a phone call conversation with Sheikh Hasina, Prime Minister of Bangladesh, on May 20.

During the talks, President Xi reassured Prime Minister Hasina of standing by Bangladesh as the truest friend in this all-out war against COVID-19. 

Bangladesh on Sunday reported 3,531 new COVID-19 cases in the last 24 hours, raising the total number of confirmed cases to 112,306.

In the last 24 hours, 39 more patients lost their lives, raising the death toll to 1,464.

During this period, 60 laboratories across the country tested 15,585 samples. So far, 612,164 samples have been tested.

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.